hVIVO (LON:HVO) Insider Buys £31,200 in Stock

hVIVO plc (LON:HVO) insider Stephen Pinkerton purchased 520,000 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were acquired at an average cost of GBX 6 per share, for a total transaction of £31,200.

hVIVO Stock Performance

Shares of LON HVO opened at GBX 6.63 on Thursday. hVIVO plc has a 12-month low of GBX 4.31 and a 12-month high of GBX 22. The company has a market cap of £45.53 million, a PE ratio of 8.60 and a beta of 0.97. The stock has a 50 day simple moving average of GBX 6.25 and a 200-day simple moving average of GBX 8.65. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86.

hVIVO (LON:HVO) last announced its earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. On average, equities research analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Shore Capital cut their price objective on shares of hVIVO from GBX 35 to GBX 25 and set a “buy” rating on the stock in a research note on Tuesday, September 23rd. Peel Hunt reiterated an “add” rating and issued a GBX 10 target price on shares of hVIVO in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of GBX 17.50.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.